欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > MAPK > LGX 818

浏览历史

S81273

LGX 818

源叶(MedMol) 99%
  • 英文名:
  • LGX 818
  • 别名:
  • UNII-8L7891MRB6; methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate; LGX-818; Encorafenib; (S)-methyl (1-
  • CAS号:
  • 1269440-17-6
  • 分子式:
  • C22H27ClFN7O4S
  • 分子量:
  • 540.01
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S81273-1mg 99% ¥200.00元 10 - - - EA 加入购物车
源叶(MedMol) S81273-5mg 99% ¥600.00元 6 - - - EA 加入购物车
源叶(MedMol) S81273-10mg 99% ¥900.00元 6 - - - EA 加入购物车
源叶(MedMol) S81273-50mg 99% ¥2600.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
  • 靶点: Raf
  • 体内研究:
    LGX818 treatment at oral doses as low as 6 mg/kg resulted in strong (75%) and sustained (>24 hours) decrease in phospho-MEK, even following clearance of drug from circulation in single dose PK/PD studies in human melanoma xenograft models (BRAFV600E). LGX818 induces tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1 mg/kg. Consistent with the in vitro data, LGX818 is inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid, with good tolerability and linear increase in exposure. Efficacy is also achieved in a more disease-relevant spontaneous metastatic melanoma and a model of melanoma brain metastasis. LGX818 is a potent and selective RAF kinase inhibitor with unique biochemical properties that contribute to an excellent pharmacological profile.
  • 细胞实验: LGX818 is dissolved in DMSO. A375 is a melanoma cell line that harbors the B-Raf V600E mutation. A375-luc cells engineered to express luciferase is plated to 384-well white clear bottom plates as 1,500 cells/50 μL/well in DMEM containing 10% FBS. Test compounds, dissolved in 100% DMSO at appropriate concentrations, are transferred to the cells by a robotic Pin Tool (100 mL). The cells are incubated for 2 days at 25°C, then 25 μL of BrightGloTM is added to each well and the plates are read by luminescence. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software. wild type and V600E B-Raf.
  • 参考文献:
    1.Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790
  • 溶解性: Ethanol:93  mg/mL  (172.2  mM)    DMSO:93  mg/mL  (172.2  mM)    H2O:<1  mg/mL
  • 保存条件: 2-8℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.852 ml 9.259 ml 18.518 ml
    5 mM 0.37 ml 1.852 ml 3.704 ml
    10 mM 0.185 ml 0.926 ml 1.852 ml
    50 mM 0.037 ml 0.185 ml 0.37 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。